Relation of SARS-CoV-2 Reinfection to Cellular Immunity

August 31, 2020
Grant M. Gallagher

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at USP, discusses the recent report of SARS-CoV-2 reinfection.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia (USP), discusses the recent report of SARS-CoV-2 reinfection.

  • Are these reports consistent with immunity from past viruses?
  • How does cellular memory work?

About US Pharmacopeia:

When you look at a prescription in the United States, you're likely to see "USP" written on the bottle. The same goes for an increasing number of over-the-counter supplements, as vitamin manufacturers look to reassure potential patients in a crowded and opaque market.

Originally formed by a collective of doctors looking to ensure shared quality control, USP has grown into an institutional authority over the years. If a drug ingredient or product has an applicable USP quality standard, it must conform in order to use the designation "USP."

"As the world gets smaller and more connected, quality issues affect everyone. Diseases travel. Drug resistance grows. Fake medicines kill. The foundation of quality we’re building helps address these and other global health issues. Whether decreasing the prevalence of substandard and poor-quality medicines or helping to curb antimicrobial resistance, we’re there working to protect the health of people all over the world." - USP, About Us